Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 05/22/2019 (Notice of voluntarily dismissal)

Filing Date: March 11, 2019

According to the Complaint, on February 21, 2019, defendants issued a joint press release announcing they had entered into an Agreement and Plan of Merger dated February 20, 2019. Pursuant to the terms of the Merger Agreement, on March 5, 2019, Purchaser commenced the Tender Offer to purchase all outstanding shares of Immune Design for $5.85 per share of Immune Design common stock. The Tender Offer is scheduled to expire at one minute following 11:59 p.m., Eastern Time, on April 1, 2019. The Proposed Transaction is valued at approximately $300 million.

On March 5, 2019, defendants filed a Solicitation/Recommendation Statement on Schedule 14D-9 (the “Recommendation Statement”) with the U.S. Securities and Exchange Commission. The Complaint alleges the Recommendation Statement, which recommends that Immune Design stockholders tender their shares in favor of the Proposed Transaction, omits or misrepresents material information concerning, among other things: (i) Immune Design management’s financial projections utilized by the Company’s financial advisor Lazard Frères & Co. LLC (“Lazard”) in its financial analyses; (ii) the data and inputs underlying the financial valuation analyses that support the fairness opinion provided by Lazard; and (iii) potential conflicts of interest faced by Company insiders.

This case was voluntarily dismissed on May 22, 2019.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: IMDZ
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: W.D. Washington
DOCKET #: 19-CV-00350
JUDGE: Hon. Thomas S. Zilly
DATE FILED: 03/11/2019
CLASS PERIOD END: 03/11/2019
  1. Breskin Johnson Townsend PLLC
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available